Close Banner
Free Section  - CAP Smart Takes

05. Disparities in Pharmacologic Restraint Use in Pediatric Emergency Departments

Published on April 1, 2023 Certification expiration date: April 1, 2026

David R. Rosenberg, M.D.

Chair of the Department of Psychiatry & Behavioral Neuroscience - Wayne State University School of Medicine

Key Points

  • Black patients were found to be significantly more likely to experience pharmacologic restraint than White patients, raising questions about potential explicit or implicit bias.
  • Behavioral interventions and staff training can significantly decrease the need for pharmacologic restraint by promoting proactive approaches to handling agitation and aggression.

Free Downloads for Offline Access

  • Free Download Audio File (MP3)

Text version

Hi! David Rosenberg here for the Psychopharmacology Institute. In this CAP—or Child and Adolescent Psychiatry—Smart Take, we will look closely at disparities in the use of pharmacologic restraints in pediatric emergency departments. Now, we know that emergency department use by children with mental and behavioral conditions is skyrocketing, not uncommonly resulting in boarding in the emergency department and extended stays. Many families in our pediatric emergency department use the emergency room as their primary site for addressing behavioral and mental health conditions and concerns. This is not surprising in a complex and often challenging mental health system that is all too often overwhelmed and understaffed. Decreased inpatient psychiatry beds in the community further complicate and challenge pediatric emergency departments with extended stays of youth with behavioral and mental health conditions.

So, in this multicenter study described by Foster and colleagues, emergency department visits from over 540,000 youth with a primary mental or behavioral diagnosis of 3–21 years of age were analyzed between 2010–20. Over 22,000 visits, or just over 4%, involved pharmacologic restraint. Pharmacologic restraint was predicted with ages 18–21 years, male sex, Black race, visits starting during the weekend or overnight when staffing is usually less intense, and repeat visits for mental or behavioral health conditions. Interestingly, pharmacologic restraint decreased as the average annual emergency department volume of youth with mental or behavioral health conditions increased. This may be due to emergency departments with more patients with mental or behavioral conditions. They may get more experience, dedicate more resources to these patients, and become more comfortable handling behavioral and mental health patients in the emergency department.

Now, the authors of this article also did a deep dive and took a close look at potential healthcare disparities in pharmacological restraint. They found that Black patients were significantly more likely to have pharmacologic restraint than White patients. This is very important and raises many questions about possible biases resulting from explicit or implicit bias. Moreover, it also raises opportunities for quality improvement using standardized protocols and various quality improvement initiatives to ensure that all patients are treated the same, or at least in the same manner, that can minimize the risk of these racial or ethnic disparities.

Although we have focused primarily on pharmacologic restraint, there are behavioral interventions that can significantly decrease the need for pharmacologic restraint. This includes staff training in how to react to youth and their families and to be proactive rather than reactive in terms of intervening before the situation gets out of control regarding agitation and aggression. Our department has developed what we call a Compassionate Care Training Program where we train nonmental health personnel and emergency departments, as well as medical and surgical inpatient units, outpatient clinics, group homes, and more, on how to assess better and be alert for behavioral dyscontrol, and which strategies can be used to prevent or reduce its occurrence. Part of this may involve decreasing external stimuli around an agitated patient, being attentive, checking back in with patients and families, and identifying families who seem upset or children, adolescents, and families who are nervous and have been asking for more information.

The Compassionate Care Training we developed is a behavioral analog to ACLS with vignettes, role play, and interactive training to become more comfortable and adept when interacting with patients with mental and behavioral health conditions. We would not expect a physician with no training at all to go in and do advanced cardiac life support. Similarly, in psychiatric behavioral dyscontrol in an emergency room setting—sometimes unexpected, sometimes with decreased resources—we should not expect that someone with no training in the behavioral aspects would be able to walk in and do things perfectly.

My experience or postmortems about agitation and aggression in our work convinces me that many pharmacologic restraints are preventable. Now, there is no doubt that some are not, and even with the best care, pharmacologic restraint is necessary. However, pharmacologic restraint can often be prevented or minimized if the right behavioral policies are in place and people are trained to be proactive rather than reactive. Moreover, some aspects can be straightforward. For example, I am a child and adolescent psychiatrist. Can you guess the one word I never use with my pediatric patients? I will give you a hint: It is 1 syllable. The word is “no” because it immediately changes the dynamic when I say no to a child or adolescent. This does not mean I agree and do whatever the child or adolescent wants—quite the contrary.

However, rather than starting with no and getting the adolescent or child in a defensive posture, where there is immediately some confrontation, I like to take that away, show the person that I am listening to them, and that I realize their concerns are valid, do what I can to bond with a particular child. This does not mean it always works and you can bond with every adolescent or child. However, in my experience, this can be quite successful and can often defuse certain opposition and concerns in children or adolescents. I am letting them know that I hear their concerns. I want to address them. I want to look for ways to ally. Much of the training in terms of compassionate care is far more complex than just not saying the word no.

However, the principle is the same: To retrain the brain, to retrain our limbic system in terms of emotions and how we process emotions, and to think proactively about approaches and how to keep everyone safe, prevent, minimize, and be ready and not unprepared for aggression or agitation. The bottom line is that this is an important early paper reflecting a growing national epidemic of skyrocketing youth visits to the emergency department for mental health and behavioral conditions. The healthcare disparities are meriting attention, and we are training in implicit and explicit bias and developing standardized protocols, which may help significantly reduce these biases.

Abstract

Disparities in Pharmacologic Restraint Use in Pediatric Emergency Departments

Ashley A Foster, John J Porter, Michael C Monuteaux, Jennifer A Hoffmann, Joyce Li, Lois K Lee, Joel D Hudgins

Objectives: Emergency department (ED) utilization by children with mental and behavioral health (MBH) conditions is increasing. During these visits, pharmacologic restraint may be used to manage acute agitation. Factors associated with pharmacologic restraint use are not well described.

Methods: This was a retrospective cohort study of ED visits from the Pediatric Health Information System database, 2010-2020. We included visits by children 3-21 years with a primary MBH diagnosis and identified visits with pharmacologic restraint. Regression models were used to analyze the association between patient- and hospital-level factors and restraint.

Results: Of 545 800 ED MBH visits over the study period, 22 194 visits (4.1%) involved pharmacologic restraint use. In multivariable analysis, restraint was associated with ages 18-21 years (odds ratio [OR], 1.88; 95% confidence interval [CI], 1.59-2.22), male sex (OR, 1.25; 95% CI, 1.16-1.34), Black race (OR, 1.22; 95% CI, 1.09-1.35), visits starting overnight (OR, 1.68; 95% CI, 1.45-1.96), or the weekend (OR, 1.26; 95% CI, 1.22-1.30), and repeat ED visits (OR, 1.31; 95% CI, 1.17-1.47). Every 100-visit increase in average annual MBH volume was associated with a 0.09% decrease in restraint (95% CI, -0.15 to -0.04) with no significant association between average annual ED volume and restraint (95% CI, -0.25 to 0.25).

Conclusions: For children in the ED with MBH conditions, ages 18-21 years, male sex, Black race, visits starting overnight or the weekend, and repeat ED visits were associated with pharmacologic restraint. These results can inform strategies to reduce restraint use and ensure safe and equitable ED care.

Free Files
Success!
Check your inbox, we sent you all the materials there.

Reference

Foster, A. A., Porter, J. J., Monuteaux, M. C., Hoffmann, J. A., Li, J., Lee, L. K., & Hudgins, J. D. (2023).

Disparities in Pharmacologic Restraint Use in Pediatric Emergency Departments

Pediatrics, 151

(1), e2022056667.

Table of Contents

Learning Objectives:

  1. Understand that balovaptan failed to significantly improve socialization and communication in children and adolescents with ASD.
  2. Understand that no substantial link exists between ADHD medications and the risk of cardiovascular disease in children, adolescents, and adults with ADHD.
  3. Recognize the association between being younger within school grades and a higher prevalence of psychostimulant prescriptions among preterm and term populations.
  4. Understand the clinical relevance of long-lasting antipsychotics for children and adolescents.
  5. Identify the factors associated with the increased utilization of pharmacologic restraints in pediatric emergency departments.

Original Release Date: April 1, 2023

Review and Re-release Date: March 1, 2024

Expiration Date: April 1, 2026

Expert: David Rosenberg, M.D.

Medical Editor: Lorena Rodriguez, M.D.

Relevant Financial Disclosures: 

None of the faculty, planners, and reviewers for this educational activity have relevant financial relationships to disclose during the last 24 months with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Contact Information: For questions regarding the content or access to this activity, contact us at support@psychopharmacologyinstitute.com

Instructions for Participation and Credit:

Participants must complete the activity online during the valid credit period that is noted above.

Follow these steps to earn CME credit:

  1. View the required educational content provided on this course page.

  2. Complete the Post Activity Evaluation for providing the necessary feedback for continuing accreditation purposes and for the development of future activities. NOTE: Completing the Post Activity Evaluation after the quiz is required to receive the earned credit.

  3. Download your certificate.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Medical Academy LLC and the Psychopharmacology Institute. Medical Academy is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

Medical Academy designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Free Files
Success!
Check your inbox, we sent you all the materials there.
Continue in the website
Instant access modal

Become a Silver, Gold, Silver extended or Gold extended Member.

2025–26 Psychopharmacology CME Program

Unlock up to 155 CME Credits, including 40 SA CME Credits.